Procalamine

Hyperphosphataemia, Communicable Diseases, Dialysis therapy + 4 more
Treatment
2 FDA approvals
6 Active Studies for Procalamine

What is Procalamine

Calcium acetateThe Generic name of this drug
Treatment SummaryValine is an important amino acid that helps with muscle growth and tissue repair. It also has stimulant properties and is used in the production of antibiotics.
ProcalAmineis the brand name
image of different drug pills on a surface
Procalamine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
ProcalAmine
Calcium acetate
1982
77

Approved as Treatment by the FDA

Calcium acetate, otherwise known as ProcalAmine, is approved by the FDA for 2 uses which include Kidney Failure, Chronic and Hyperphosphataemia .
Kidney Failure, Chronic
Helps manage End-stage Renal Failure (ESRF)
Hyperphosphataemia
Helps manage Hyperphosphataemia

Effectiveness

How Procalamine Affects PatientsL-valine is an essential amino acid, which helps build and repair muscles. It also works to lower blood sugar levels and increase growth hormone production. It is important for children's growth and adults' overall health. When taken as a supplement, it is best to combine it with isoleucine and leucine in the ratio of 2:1:2. Without enough L-valine in your diet, you may experience slowed growth, neurological issues, or anemia. It is used in both the pharmaceutical and food industries.
How Procalamine works in the bodyValine, Leucine and Isoleucine are essential amino acids that humans cannot produce, so they must be consumed in the diet. These three amino acids are broken down in muscles, producing energy that is used to make ATP. All three use the same two enzymes in the first two steps of breakdown, then their pathways diverge. Valine is turned into a glucogenic compound, while Isoleucine is both glucogenic and ketogenic. Leucine is converted into ketogenic compounds. When these pathways are disrupted, it is called Maple Syrup Urine Disease and can lead to mental retardation and poor myelin

When to interrupt dosage

The advocated measure of Procalamine is contingent upon the diagnosed state, which may include amino acid supplementation, Encephalopathies and Uremic Encephalopathy. The amount of dosage also relies on the technique of delivery (e.g. Intravenous or Solution - Intravenous) detailed in the following table.
Condition
Dosage
Administration
Astringent
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
high phosphate levels
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Hyperphosphataemia
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Kidney
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Communicable Diseases
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Dialysis therapy
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Kidney Failure, Chronic
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral

Warnings

Procalamine Contraindications
Condition
Risk Level
Notes
Hypercalcemia
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Procalamine.
Common Procalamine Drug Interactions
Drug Name
Risk Level
Description
Technetium Tc-99m oxidronate
Major
Calcium acetate may decrease effectiveness of Technetium Tc-99m oxidronate as a diagnostic agent.
Dobutamine
Minor
The therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium acetate.
3-Aza-2,3-Dihydrogeranyl Diphosphate
Moderate
Calcium acetate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acebutolol
Moderate
The therapeutic efficacy of Acebutolol can be decreased when used in combination with Calcium acetate.
Acetyldigitoxin
Moderate
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin.
Procalamine Toxicity & Overdose RiskTaking too much of branched-chain amino acids (BCAAs) can lead to dangerously low blood sugar levels and a higher risk of death in those with ALS.

Procalamine Novel Uses: Which Conditions Have a Clinical Trial Featuring Procalamine?

At present, no active trials are investigating the potential of Procalamine to address Uremic Encephalopathy, Encephalopathies and Hepatic coma.
Condition
Clinical Trials
Trial Phases
high phosphate levels
0 Actively Recruiting
Kidney Failure, Chronic
2 Actively Recruiting
Not Applicable
Communicable Diseases
0 Actively Recruiting
Hyperphosphataemia
0 Actively Recruiting
Dialysis therapy
4 Actively Recruiting
Not Applicable, Phase 1
Astringent
0 Actively Recruiting
Kidney
0 Actively Recruiting

Patient Q&A Section about procalamine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is ProcalAmine used for?

"ProcalAmine is a medication indicated for adults who are mildly catabolic and require short-term parenteral nutrition. It is used to preserve body protein and improve nitrogen balance."

Answered by AI

Is ProcalAmine PPN or TPN?

"ProcalAmine is a mixture of glycerol 3% and amino acid 3% that can be heat sterilized and supplied commercially. This product is used as PPN in some institutions."

Answered by AI

How is ProcalAmine administered?

"ProcalAmine was most commonly administered through central catheters 86% of the time, and through peripheral catheters only 14% of the time. Out of all the cases, the overall mechanical complication rate was 19%. Out of the 36 dogs, metabolic complications that could possibly be associated with ProcalAmine administration were found in 12 of them."

Answered by AI

Is ProcalAmine still available?

"The company has stopped making FreAmine III and ProcalAmine."

Answered by AI

Clinical Trials for Procalamine

Have you considered Procalamine clinical trials? We made a collection of clinical trials featuring Procalamine, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top